This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMarrone Bio Innovations（0MB）株式概要Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. 詳細0MB ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長2/6過去の実績0/6財務の健全性2/6配当金0/6報酬収益は年間24.91%増加すると予測されています リスク分析German市場と比較して、過去 3 か月間の株価の変動が非常に大きいキャッシュランウェイが1年未満である 過去1年間で株主の希薄化が進んだ すべてのリスクチェックを見る0MB Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.96該当なし内在価値ディスカウントEst. Revenue$PastFuture-41m135m2016201920222025202620282031Revenue US$134.9mEarnings US$12.7mAdvancedSet Fair ValueView all narrativesMarrone Bio Innovations, Inc. 競合他社K+SSymbol: XTRA:SDFMarket cap: €2.6bAlzChem GroupSymbol: XTRA:ACTMarket cap: €1.7bH&R GmbH KGaASymbol: XTRA:2HRAMarket cap: €178.7mIBU-tec advanced materialsSymbol: XTRA:IBUMarket cap: €78.9m価格と性能株価の高値、安値、推移の概要Marrone Bio Innovations過去の株価現在の株価US$0.9652週高値US$1.2552週安値US$0.49ベータ0.361ヶ月の変化-7.21%3ヶ月変化14.20%1年変化-18.22%3年間の変化-24.94%5年間の変化2.88%IPOからの変化-56.22%最新ニュースお知らせ • Jul 14+ 2 more updatesMarrone Bio Innovations, Inc.(NasdaqCM:MBII) dropped from NASDAQ Composite IndexMarrone Bio Innovations, Inc. will be removed from NASDAQ Composite Index.お知らせ • Jul 13Marrone Bio Innovations, Inc. Announces Kevin Helash Will Be Step Down as Chief Executive OfficerBioceres Crop Solutions Corp. announced the successful completion of its previously announced integration of Marrone Bio Innovations, Inc. Mr. Kevin Helash will be stepping down from his role as Chief Executive Officer of MBI.お知らせ • Jun 26Marrone Bio Innovations, Inc.(NasdaqCM:MBII) dropped from Russell 2000 Dynamic IndexMarrone Bio Innovations, Inc.(NasdaqCM:MBII) dropped from Russell 2000 Dynamic IndexReported Earnings • May 13First quarter 2022 earnings released: US$0.042 loss per share (vs US$0.019 loss in 1Q 2021)First quarter 2022 results: US$0.042 loss per share (down from US$0.019 loss in 1Q 2021). Revenue: US$11.1m (flat on 1Q 2021). Net loss: US$7.60m (loss widened 133% from 1Q 2021). Over the next year, revenue is forecast to grow 35%, compared to a 6.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.お知らせ • May 12Marrone Bio Innovations, Inc. Provides Revenue Guidance for the First Half of 2022Marrone Bio Innovations, Inc. provided revenue guidance for the first half of 2022. The company forecasting low- to mid-teens percentage revenue growth for the first half of 2022, which would represent a material increase above its sales growth in the first half of 2021.Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Marrone Bio Innovations no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$886.0k in 2023. New consensus forecast suggests the company will make a loss of US$4.10m in 2023.最新情報をもっと見るRecent updatesお知らせ • Jul 14+ 2 more updatesMarrone Bio Innovations, Inc.(NasdaqCM:MBII) dropped from NASDAQ Composite IndexMarrone Bio Innovations, Inc. will be removed from NASDAQ Composite Index.お知らせ • Jul 13Marrone Bio Innovations, Inc. Announces Kevin Helash Will Be Step Down as Chief Executive OfficerBioceres Crop Solutions Corp. announced the successful completion of its previously announced integration of Marrone Bio Innovations, Inc. Mr. Kevin Helash will be stepping down from his role as Chief Executive Officer of MBI.お知らせ • Jun 26Marrone Bio Innovations, Inc.(NasdaqCM:MBII) dropped from Russell 2000 Dynamic IndexMarrone Bio Innovations, Inc.(NasdaqCM:MBII) dropped from Russell 2000 Dynamic IndexReported Earnings • May 13First quarter 2022 earnings released: US$0.042 loss per share (vs US$0.019 loss in 1Q 2021)First quarter 2022 results: US$0.042 loss per share (down from US$0.019 loss in 1Q 2021). Revenue: US$11.1m (flat on 1Q 2021). Net loss: US$7.60m (loss widened 133% from 1Q 2021). Over the next year, revenue is forecast to grow 35%, compared to a 6.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.お知らせ • May 12Marrone Bio Innovations, Inc. Provides Revenue Guidance for the First Half of 2022Marrone Bio Innovations, Inc. provided revenue guidance for the first half of 2022. The company forecasting low- to mid-teens percentage revenue growth for the first half of 2022, which would represent a material increase above its sales growth in the first half of 2021.Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Marrone Bio Innovations no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$886.0k in 2023. New consensus forecast suggests the company will make a loss of US$4.10m in 2023.Breakeven Date Change • Mar 30No longer forecast to breakevenThe 2 analysts covering Marrone Bio Innovations no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$886.0k in 2023. New consensus forecast suggests the company will make a loss of US$4.10m in 2023.お知らせ • Mar 29Marrone Bio Innovations, Inc. Provides Revenue Guidance for the First Half of 2022Marrone Bio Innovations, Inc. announced that the company anticipates revenue growth for the first half of 2022 will significantly outpace rate of growth in the first half of 2021, with sales in the second quarter exceeding those in the first quarter, in line with ur typical pattern.お知らせ • Feb 24Marrone Bio Innovations, Inc. Announces Chief Financial Officer ChangesMarrone Bio Innovations, Inc. announced a transition of its Chief Financial Officer role. Current CFO Sue Cheung has chosen to resign for personal reasons, effective March 9, 2022. LaDon Johnson, a director with CFO Systems, has been appointed interim CFO on a consulting basis while the company begins a national search for a permanent CFO. Mr. Johnson has more than 30 years of experience in global corporate finance in the agriculture, food, renewables and biotechnology sectors. Previous roles include serving as CFO for an international biotechnology company and as Managing Director and CFO for the fifth large crop seed company in the world.お知らせ • Jan 19Marrone Bio Innovations, Inc. Provides Revenue Guidance for the Full Year 2021Marrone Bio Innovations, Inc. provided revenue guidance for the full year 2021. The company expected revenue growth for the full year 2021 would be in line with forecasts.お知らせ • Dec 09Marrone Bio’S Next-Generation Product for Environmentally Sustainable Pest Control Demonstrates Substantial Yield Gains in 2021 Field TrialsField trials in 2021 for Marrone Bio Innovations’ next-generation product for environmentally sustainable control of yield-robbing pests in corn and soybeans demonstrated excellent efficacy with substantial yield gains at reduced application rates. MBI-306 will offer corn growers a new alternative in treating for corn rootworm, a pest that accounts for more than $1 billion of crop damage annually1. When tested as a seed treatment to control corn rootworm larvae, MBI-306 improved corn yields by up to 23 bushels per acre, a 14% increase when compared with untreated seed. This bioinsecticide also outperformed the leading commercial standard, delivering a 4% yield advantage. These yield gains equate to an estimated return on investment of $131 per acre versus untreated seed and $41 per acre versus current commercial products. Similar benefits were demonstrated against soybean cyst nematode, the leading pest in soybeans and contributor to more than $1 billion in crop damage2. As a seed treatment, MBI-306 increased soybean yields by 11 bushels an acre, a 19% improvement and $130 per acre in additional revenue versus untreated seed. This novel bionematicide also showed excellent control with 6% higher yields when compared with commonly used treatments, providing growers an additional $47 per acre in returns. Marrone Bio is an international leader in sustainable bioprotection and plant health solutions, with 18 commercial products and 15 products in its research and development pipeline, including MBI-306. MBI-306 is a second-generation novel bioinsecticide/bionematicide built on the same proprietary microbe that serves as the active ingredient in the company’s Venerate® XC Bioinsecticide and Majestene® Bionematicide. MBI-306 was recently submitted to the U.S. Environmental Protection Agency for approval and is anticipated to be commercially available for the 2023/2024 growing season. It has shown to be non-toxic to humans, wildlife, aquatic life, earthworms and pollinators.Breakeven Date Change • Nov 24No longer forecast to breakevenThe 6 analysts covering Marrone Bio Innovations no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$886.0k in 2023. New consensus forecast suggests the company will make a loss of US$3.96m in 2023.Reported Earnings • Nov 11Third quarter 2021 earnings released: US$0.028 loss per share (vs US$0.04 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$9.86m (up 12% from 3Q 2020). Net loss: US$4.95m (loss narrowed 18% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.お知らせ • Oct 01Marrone Bio Innovations, Inc. Advances Novel HerbicidesMarrone Bio Innovations, Inc. is advancing three novel bioherbicides in its research and development pipeline, further strengthening its position as a leading provider of sustainable agricultural solutions. These biologically based herbicides are a key component of the company’s strategic growth plan, and provide entry into the $27 billion weed control market. Marrone Bio has three proprietary bioherbicides in its R&D portfolio. The first two, MBI-005 and MBI-011, have prior regulatory approval from the U.S. Environmental Protection Agency, and now are undergoing further formulation refinement. The third, MBI-014/015, has progressed to advanced stages of development. Current results indicate that MBI-014/015 has herbicidal properties estimated to be 50-to-100 times more active than leading chemical alternatives. The MBI family of bioherbicides can control the most economically significant and resistant weeds, including annual broadleaves, grasses and sedges in major row crops as well as vegetable and turf markets. The products can be used at various points in the growing season to give farmers maximum flexibility to control weeds before, during and after planting. From the more than 12,000 microbes screened, the company’s R&D team has discovered approximately 500 herbicidal microbes that can be advanced through genomics, bioinformatics and synthetic biology systems. This broad library of microbes can potentially lead to the discovery of additional novel active ingredients and new modes of action.Breakeven Date Change • Sep 23Forecast to breakeven in 2023The 6 analysts covering Marrone Bio Innovations expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$886.0k in 2023. Average annual earnings growth of 68% is required to achieve expected profit on schedule.お知らせ • Sep 10Marrone Bio Innovations, Inc. Prepares to Submit Registration for Next-Generation Crop Protection Product in North AmericaMarrone Bio Innovations, Inc. is on track to submit MBI-306, its next generation nematicide/insecticide, to regulatory authorities in the United States within the coming weeks. Destined for row and specialty crop markets globally, MBI-306 and its variants have been proven to perform as well as synthetic counterparts both in terms of efficacy and return on investment to growers. The product is well positioned to be an important component of the $15.7 billion global insecticide market1, and is expected to generate peak potential incremental revenue for MBI in excess of $100 million. MBI-306 and its variants are built on a proprietary microbe that has been the foundation of the company’s Venerate® Bioinsecticide and Majestene Bionematicide crop protection products. MBI-306 is proven to be efficacious against a broad spectrum of yield-robbing insects and nematodes, including corn rootworm larvae, often referred to as the billion-dollar pest in the United States. In addition to the regulatory submission of MBI-306, MBI is in the final stages of preparing to submit MBI-206 -- a popular bionematicide seed treatment used on more than 10 million acres in the United States -- to Brazilian regulatory authorities. This will serve to further expand the company’s geographic footprint in one of the world’s large corn and soybean markets with an estimated insecticide value of $2 billion in 2020. In addition to its impressive commercial performance, MBI-206 has also been evaluated for climate impact by a third-party, Boundless Impact Research and Analytics, and received an ‘outstanding’ score of 9.8 out of 10. Given the similarities in both products, MBI-306 is expected to receive an equally advantageous score and will be evaluated in the coming months. Commercial launch for both products is expected in 2023/2024.Executive Departure • Sep 09Chief Manufacturing Officer Kevin Hammill has left the companyOn the 6th of September, Kevin Hammill's tenure as Chief Manufacturing Officer ended after 3.3 years in the role. As of June 2021, Kevin still personally held 207.90k shares (€291k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 3.33 years.Reported Earnings • Aug 18Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.019 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: US$12.6m (up 3.4% from 2Q 2020). Net loss: US$3.04m (loss widened 5.7% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.お知らせ • Jun 28+ 4 more updatesMarrone Bio Innovations, Inc.(NasdaqCM:MBII) dropped from Russell 3000E Value IndexMarrone Bio Innovations, Inc.(NasdaqCM:MBII) dropped from Russell 3000E Value IndexReported Earnings • May 15First quarter 2021 earnings released: US$0.019 loss per share (vs US$0.05 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$11.0m (up 14% from 1Q 2020). Net loss: US$3.26m (loss narrowed 54% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.お知らせ • Apr 29Marrone Bio Innovations, Inc. Provides Revenue Forecast for Full Year 2021Marrone Bio Innovations, Inc. increased revenue forecast for full year 2021. For the year, the company now expects revenue growth to the upper 20% range.Reported Earnings • Mar 27Full year 2020 earnings released: US$0.14 loss per share (vs US$0.32 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$38.4m (up 31% from FY 2019). Net loss: US$20.2m (loss narrowed 46% from FY 2019). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 11Marrone Bio Innovations, Inc. to Report Q4, 2020 Results on Mar 23, 2021Marrone Bio Innovations, Inc. announced that they will report Q4, 2020 results at 4:30 PM, US Eastern Standard Time on Mar 23, 2021お知らせ • Feb 26Marrone Bio Innovations, Inc., Annual General Meeting, May 26, 2021Marrone Bio Innovations, Inc., Annual General Meeting, May 26, 2021.Executive Departure • Feb 24President & CFO James Boyd has left the companyOn the 18th of February, James Boyd's tenure as President & CFO ended after 3.5 years in the role. As of December 2020, James personally held 109.29k shares (€108k worth at the time). A total of 2 executives have left over the last 12 months.Executive Departure • Feb 19President & CFO James Boyd has left the companyOn the 18th of February, James Boyd's tenure as President & CFO ended after 3.5 years in the role. As of December 2020, James personally held 109.29k shares (€108k worth at the time). A total of 2 executives have left over the last 12 months.お知らせ • Feb 04Marrone Bio Innovations, Inc. Announces Executive ChangesMarrone Bio Innovations, Inc. announced that Kevin Hammill will take on a new role as Chief Manufacturing and Supply Chain Officer. Kevin was critical in revamping and growing the commercial organization in short order, and his leadership as Chief Commercial Officer has played a major role in their success. Matti Tiainen is being promoted to Senior Vice President of International Sales, with responsibilities for their commercial activities in EMEA/CIS, South America and Asia Pacific. Tim Knight will be sharing commercial responsibilities with Matti as Senior Director of Sales, North and Central America. While relatively new to Marrone Bio, Tim has more than 30 years of experience in agriculture with excellent skills in sales, marketing, product development and channel management.Is New 90 Day High Low • Jan 30New 90-day high: €1.34The company is up 44% from its price of €0.93 on 30 October 2020. The German market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 28% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.60 per share.お知らせ • Jan 29Marrone Bio Innovations, Inc. Announces Management ChangesMarrone Bio Innovations, Inc. announced that Suping (Sue) Cheung has been appointed Chief Financial Officer, effective Feb. 18, 2021. She succeeds James Boyd, who previously announced his intention to retire. Cheung, a certified public accountant, brings to Marrone Bio 28 years of experience in international strategic and financial operations, including financial reporting, forecasting and budgeting; mergers and acquisitions; equity and debt financing; internal controls; and investor relations. Most recently, she was the chief financial officer for QuickLogic Corporation (NASDAQ: QUIK) for five years, and corporate controller in the eight years before that promotion. Prior to QuickLogic, she has held senior roles at both publicly traded and privately held companies in accounting, finance and operational management, and began her career as an auditor and tax consultant at PricewaterhouseCoopers (PwC).お知らせ • Jan 15Marrone Bio Innovations Recently Receives Approval for Grandevo WDG Bioinsecticide for Use in New Zealand and ChileMarrone Bio Innovations, Inc. announced that it recently received approval for Grandevo WDG Bioinsecticide for use in New Zealand and Chile. Grandevo WDG and Grandevo CG have also been approved for use on hemp by the U.S. Environmental Protection Agency (EPA). In New Zealand, Grandevo WDG will be sold by Nufarm as BioGro® and is approved for controlling mealybug on New Zealand’s famous wine grape crop. BioGro is registered and approved by Sustainable Winegrowing NZ™ (SWNZ), a sustainability program for growing wine grapes, and is allowed for use on both organic and conventional grape-growing systems from pre-flowering to bunch closure. Additional crops and pests are expected for approval in the coming year. Grandevo WDG was approved for use in blueberries, grapes, stone fruit, tomatoes, avocados, and onions by the Ministry of Agriculture in Chile (Servicio Agricola y Ganadero - SAG) in November 2020 and is distributed by Anasac, a leading Chilean agriculture inputs provider. Grandevo WDG was among one of the first products of its kind to be approved under SAG’s new regulatory guidance (No. 9074/2018) for biological pesticides, as published in December 2018. Chile is a major exporter of fresh blueberries and grapes and accounts for 60% of all fruit exports within South America. In the U.S., Grandevo WDG and Grandevo CG were recently approved by the EPA for use on hemp, a high-value crop that has seen rapid growth since its authorization for cultivation in the 2014 U.S. Farm Bill. The approval of the bioinsecticide will provide growers with some much-needed help in the management of problematic pests such as thrips and mites and comes at a time when, due to the highly regulated environment of hemp growing and processing, limited crop protection products have been available. Growers are encouraged to check with their state pesticide regulatory agency or MBI for registration status and can expect state approval in time for the planting of the 2021 hemp crop.Is New 90 Day High Low • Jan 14New 90-day high: €1.12The company is up 16% from its price of €0.96 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.74 per share.Analyst Estimate Surprise Post Earnings • Nov 11Revenue misses expectationsRevenue missed analyst estimates by 15%. Over the next year, revenue is forecast to grow 47%, compared to a 3.1% growth forecast for the Chemicals industry in Germany.Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.04 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$8.83m (up 27% from 3Q 2019). Net loss: US$6.06m (loss narrowed 63% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 03Marrone Bio Innovations, Inc. Announces Appointment of Lara L. Lee as Class III DirectorMarrone Bio Innovations, Inc. announced that on November 2, 2020, following 2020 Annual Meeting, Board of Directors approved an increase in the size of the Board to eight people, with the one additional vacancy on the Board being in Class III, effective immediately. The Board appointed Lara L. Lee to fill the vacancy as a Class III director of the Company, with Ms. Lee's term to expire as of 2022 Annual Meeting of Stockholders. Ms. Lee will serve on the Audit Committee and Compensation Committee of the Board. Most recently, since 2018, Ms. Lee has served as the Chief Executive Officer of Creative Renewal. Ms. Lee currently serves on the boards of Organically Grown Company and The Sill.お知らせ • Oct 28Marrone Bio Innovations, Inc. to Report Q3, 2020 Results on Nov 09, 2020Marrone Bio Innovations, Inc. announced that they will report Q3, 2020 results on Nov 09, 2020Is New 90 Day High Low • Oct 14New 90-day low: €0.91The company is down 7.0% from its price of €0.97 on 16 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €5.94 per share.お知らせ • Sep 23+ 1 more updateJames Boyd to Retire as President of Marrone Bio Innovations, IncMarrone Bio Innovations, Inc. announced that company President James Boyd will retire from his positions. A national search process for the new Chief Financial Officer is underway, and Mr. Boyd will continue as President during the search process.お知らせ • Jul 25Marrone Bio Innovations, Inc. to Report Q2, 2020 Results on Aug 10, 2020Marrone Bio Innovations, Inc. announced that they will report Q2, 2020 results at 4:30 PM, US Eastern Standard Time on Aug 10, 2020お知らせ • Jul 07Marrone Bio Innovations, Inc. Appoints Kevin Helash as New Chief Executive OfficerMarrone Bio Innovations, Inc. announced the appointment of Kevin Helash as its new chief executive officer. Helash will join the company as early as August 1, 2020. His effective date is pending receipt of permanent residency status or the applicable visa, both of which are in process. A 28-plus-year agricultural industry veteran, Helash comes to Marrone Bio from Agrinos AS. Prior to joining Agrinos, Helash was a vice president and corporate officer with Agrium (now Nutrien Ltd.). Helash replaces Pamela Marrone, founder of Marrone Bio, who announced her intention to retire as CEO in December 2019. Marrone will remain with Marrone Bio as CEO until Helash’s first day of employment and thereafter will continue to serve as a non-employee director of the company.株主還元0MBDE ChemicalsDE 市場7D0.5%-1.3%3.9%1Y-18.2%3.6%2.6%株主還元を見る業界別リターン: 0MB過去 1 年間で3.6 % の収益を上げたGerman Chemicals業界を上回りました。リターン対市場: 0MB過去 1 年間で2.6 % の収益を上げたGerman市場を上回りました。価格変動Is 0MB's price volatile compared to industry and market?0MB volatility0MB Average Weekly Movement12.9%Chemicals Industry Average Movement6.0%Market Average Movement6.1%10% most volatile stocks in DE Market12.9%10% least volatile stocks in DE Market2.7%安定した株価: 0MB 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 0MBの weekly volatility ( 13% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2006153Kevin Helashwww.marronebio.comもっと見るMarrone Bio Innovations, Inc. 基礎のまとめMarrone Bio Innovations の収益と売上を時価総額と比較するとどうか。0MB 基礎統計学時価総額€144.25m収益（TTM）-€20.70m売上高(TTM)€43.97m3.3xP/Sレシオ-7.0xPER（株価収益率0MB は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計0MB 損益計算書（TTM）収益US$44.37m売上原価US$17.89m売上総利益US$26.48mその他の費用US$47.37m収益-US$20.89m直近の収益報告Mar 31, 2022次回決算日該当なし一株当たり利益（EPS）-0.11グロス・マージン59.69%純利益率-47.08%有利子負債／自己資本比率139.3%0MB の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2022/07/14 12:55終値2022/07/12 00:00収益2022/03/31年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Marrone Bio Innovations, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Nathan WeinsteinAegis Capital CorporationBenjamin KalloBairdRobert BurlesonCanaccord Genuity6 その他のアナリストを表示
お知らせ • Jul 14+ 2 more updatesMarrone Bio Innovations, Inc.(NasdaqCM:MBII) dropped from NASDAQ Composite IndexMarrone Bio Innovations, Inc. will be removed from NASDAQ Composite Index.
お知らせ • Jul 13Marrone Bio Innovations, Inc. Announces Kevin Helash Will Be Step Down as Chief Executive OfficerBioceres Crop Solutions Corp. announced the successful completion of its previously announced integration of Marrone Bio Innovations, Inc. Mr. Kevin Helash will be stepping down from his role as Chief Executive Officer of MBI.
お知らせ • Jun 26Marrone Bio Innovations, Inc.(NasdaqCM:MBII) dropped from Russell 2000 Dynamic IndexMarrone Bio Innovations, Inc.(NasdaqCM:MBII) dropped from Russell 2000 Dynamic Index
Reported Earnings • May 13First quarter 2022 earnings released: US$0.042 loss per share (vs US$0.019 loss in 1Q 2021)First quarter 2022 results: US$0.042 loss per share (down from US$0.019 loss in 1Q 2021). Revenue: US$11.1m (flat on 1Q 2021). Net loss: US$7.60m (loss widened 133% from 1Q 2021). Over the next year, revenue is forecast to grow 35%, compared to a 6.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
お知らせ • May 12Marrone Bio Innovations, Inc. Provides Revenue Guidance for the First Half of 2022Marrone Bio Innovations, Inc. provided revenue guidance for the first half of 2022. The company forecasting low- to mid-teens percentage revenue growth for the first half of 2022, which would represent a material increase above its sales growth in the first half of 2021.
Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Marrone Bio Innovations no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$886.0k in 2023. New consensus forecast suggests the company will make a loss of US$4.10m in 2023.
お知らせ • Jul 14+ 2 more updatesMarrone Bio Innovations, Inc.(NasdaqCM:MBII) dropped from NASDAQ Composite IndexMarrone Bio Innovations, Inc. will be removed from NASDAQ Composite Index.
お知らせ • Jul 13Marrone Bio Innovations, Inc. Announces Kevin Helash Will Be Step Down as Chief Executive OfficerBioceres Crop Solutions Corp. announced the successful completion of its previously announced integration of Marrone Bio Innovations, Inc. Mr. Kevin Helash will be stepping down from his role as Chief Executive Officer of MBI.
お知らせ • Jun 26Marrone Bio Innovations, Inc.(NasdaqCM:MBII) dropped from Russell 2000 Dynamic IndexMarrone Bio Innovations, Inc.(NasdaqCM:MBII) dropped from Russell 2000 Dynamic Index
Reported Earnings • May 13First quarter 2022 earnings released: US$0.042 loss per share (vs US$0.019 loss in 1Q 2021)First quarter 2022 results: US$0.042 loss per share (down from US$0.019 loss in 1Q 2021). Revenue: US$11.1m (flat on 1Q 2021). Net loss: US$7.60m (loss widened 133% from 1Q 2021). Over the next year, revenue is forecast to grow 35%, compared to a 6.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
お知らせ • May 12Marrone Bio Innovations, Inc. Provides Revenue Guidance for the First Half of 2022Marrone Bio Innovations, Inc. provided revenue guidance for the first half of 2022. The company forecasting low- to mid-teens percentage revenue growth for the first half of 2022, which would represent a material increase above its sales growth in the first half of 2021.
Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Marrone Bio Innovations no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$886.0k in 2023. New consensus forecast suggests the company will make a loss of US$4.10m in 2023.
Breakeven Date Change • Mar 30No longer forecast to breakevenThe 2 analysts covering Marrone Bio Innovations no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$886.0k in 2023. New consensus forecast suggests the company will make a loss of US$4.10m in 2023.
お知らせ • Mar 29Marrone Bio Innovations, Inc. Provides Revenue Guidance for the First Half of 2022Marrone Bio Innovations, Inc. announced that the company anticipates revenue growth for the first half of 2022 will significantly outpace rate of growth in the first half of 2021, with sales in the second quarter exceeding those in the first quarter, in line with ur typical pattern.
お知らせ • Feb 24Marrone Bio Innovations, Inc. Announces Chief Financial Officer ChangesMarrone Bio Innovations, Inc. announced a transition of its Chief Financial Officer role. Current CFO Sue Cheung has chosen to resign for personal reasons, effective March 9, 2022. LaDon Johnson, a director with CFO Systems, has been appointed interim CFO on a consulting basis while the company begins a national search for a permanent CFO. Mr. Johnson has more than 30 years of experience in global corporate finance in the agriculture, food, renewables and biotechnology sectors. Previous roles include serving as CFO for an international biotechnology company and as Managing Director and CFO for the fifth large crop seed company in the world.
お知らせ • Jan 19Marrone Bio Innovations, Inc. Provides Revenue Guidance for the Full Year 2021Marrone Bio Innovations, Inc. provided revenue guidance for the full year 2021. The company expected revenue growth for the full year 2021 would be in line with forecasts.
お知らせ • Dec 09Marrone Bio’S Next-Generation Product for Environmentally Sustainable Pest Control Demonstrates Substantial Yield Gains in 2021 Field TrialsField trials in 2021 for Marrone Bio Innovations’ next-generation product for environmentally sustainable control of yield-robbing pests in corn and soybeans demonstrated excellent efficacy with substantial yield gains at reduced application rates. MBI-306 will offer corn growers a new alternative in treating for corn rootworm, a pest that accounts for more than $1 billion of crop damage annually1. When tested as a seed treatment to control corn rootworm larvae, MBI-306 improved corn yields by up to 23 bushels per acre, a 14% increase when compared with untreated seed. This bioinsecticide also outperformed the leading commercial standard, delivering a 4% yield advantage. These yield gains equate to an estimated return on investment of $131 per acre versus untreated seed and $41 per acre versus current commercial products. Similar benefits were demonstrated against soybean cyst nematode, the leading pest in soybeans and contributor to more than $1 billion in crop damage2. As a seed treatment, MBI-306 increased soybean yields by 11 bushels an acre, a 19% improvement and $130 per acre in additional revenue versus untreated seed. This novel bionematicide also showed excellent control with 6% higher yields when compared with commonly used treatments, providing growers an additional $47 per acre in returns. Marrone Bio is an international leader in sustainable bioprotection and plant health solutions, with 18 commercial products and 15 products in its research and development pipeline, including MBI-306. MBI-306 is a second-generation novel bioinsecticide/bionematicide built on the same proprietary microbe that serves as the active ingredient in the company’s Venerate® XC Bioinsecticide and Majestene® Bionematicide. MBI-306 was recently submitted to the U.S. Environmental Protection Agency for approval and is anticipated to be commercially available for the 2023/2024 growing season. It has shown to be non-toxic to humans, wildlife, aquatic life, earthworms and pollinators.
Breakeven Date Change • Nov 24No longer forecast to breakevenThe 6 analysts covering Marrone Bio Innovations no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$886.0k in 2023. New consensus forecast suggests the company will make a loss of US$3.96m in 2023.
Reported Earnings • Nov 11Third quarter 2021 earnings released: US$0.028 loss per share (vs US$0.04 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$9.86m (up 12% from 3Q 2020). Net loss: US$4.95m (loss narrowed 18% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
お知らせ • Oct 01Marrone Bio Innovations, Inc. Advances Novel HerbicidesMarrone Bio Innovations, Inc. is advancing three novel bioherbicides in its research and development pipeline, further strengthening its position as a leading provider of sustainable agricultural solutions. These biologically based herbicides are a key component of the company’s strategic growth plan, and provide entry into the $27 billion weed control market. Marrone Bio has three proprietary bioherbicides in its R&D portfolio. The first two, MBI-005 and MBI-011, have prior regulatory approval from the U.S. Environmental Protection Agency, and now are undergoing further formulation refinement. The third, MBI-014/015, has progressed to advanced stages of development. Current results indicate that MBI-014/015 has herbicidal properties estimated to be 50-to-100 times more active than leading chemical alternatives. The MBI family of bioherbicides can control the most economically significant and resistant weeds, including annual broadleaves, grasses and sedges in major row crops as well as vegetable and turf markets. The products can be used at various points in the growing season to give farmers maximum flexibility to control weeds before, during and after planting. From the more than 12,000 microbes screened, the company’s R&D team has discovered approximately 500 herbicidal microbes that can be advanced through genomics, bioinformatics and synthetic biology systems. This broad library of microbes can potentially lead to the discovery of additional novel active ingredients and new modes of action.
Breakeven Date Change • Sep 23Forecast to breakeven in 2023The 6 analysts covering Marrone Bio Innovations expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$886.0k in 2023. Average annual earnings growth of 68% is required to achieve expected profit on schedule.
お知らせ • Sep 10Marrone Bio Innovations, Inc. Prepares to Submit Registration for Next-Generation Crop Protection Product in North AmericaMarrone Bio Innovations, Inc. is on track to submit MBI-306, its next generation nematicide/insecticide, to regulatory authorities in the United States within the coming weeks. Destined for row and specialty crop markets globally, MBI-306 and its variants have been proven to perform as well as synthetic counterparts both in terms of efficacy and return on investment to growers. The product is well positioned to be an important component of the $15.7 billion global insecticide market1, and is expected to generate peak potential incremental revenue for MBI in excess of $100 million. MBI-306 and its variants are built on a proprietary microbe that has been the foundation of the company’s Venerate® Bioinsecticide and Majestene Bionematicide crop protection products. MBI-306 is proven to be efficacious against a broad spectrum of yield-robbing insects and nematodes, including corn rootworm larvae, often referred to as the billion-dollar pest in the United States. In addition to the regulatory submission of MBI-306, MBI is in the final stages of preparing to submit MBI-206 -- a popular bionematicide seed treatment used on more than 10 million acres in the United States -- to Brazilian regulatory authorities. This will serve to further expand the company’s geographic footprint in one of the world’s large corn and soybean markets with an estimated insecticide value of $2 billion in 2020. In addition to its impressive commercial performance, MBI-206 has also been evaluated for climate impact by a third-party, Boundless Impact Research and Analytics, and received an ‘outstanding’ score of 9.8 out of 10. Given the similarities in both products, MBI-306 is expected to receive an equally advantageous score and will be evaluated in the coming months. Commercial launch for both products is expected in 2023/2024.
Executive Departure • Sep 09Chief Manufacturing Officer Kevin Hammill has left the companyOn the 6th of September, Kevin Hammill's tenure as Chief Manufacturing Officer ended after 3.3 years in the role. As of June 2021, Kevin still personally held 207.90k shares (€291k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 3.33 years.
Reported Earnings • Aug 18Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.019 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: US$12.6m (up 3.4% from 2Q 2020). Net loss: US$3.04m (loss widened 5.7% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
お知らせ • Jun 28+ 4 more updatesMarrone Bio Innovations, Inc.(NasdaqCM:MBII) dropped from Russell 3000E Value IndexMarrone Bio Innovations, Inc.(NasdaqCM:MBII) dropped from Russell 3000E Value Index
Reported Earnings • May 15First quarter 2021 earnings released: US$0.019 loss per share (vs US$0.05 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$11.0m (up 14% from 1Q 2020). Net loss: US$3.26m (loss narrowed 54% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
お知らせ • Apr 29Marrone Bio Innovations, Inc. Provides Revenue Forecast for Full Year 2021Marrone Bio Innovations, Inc. increased revenue forecast for full year 2021. For the year, the company now expects revenue growth to the upper 20% range.
Reported Earnings • Mar 27Full year 2020 earnings released: US$0.14 loss per share (vs US$0.32 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$38.4m (up 31% from FY 2019). Net loss: US$20.2m (loss narrowed 46% from FY 2019). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 11Marrone Bio Innovations, Inc. to Report Q4, 2020 Results on Mar 23, 2021Marrone Bio Innovations, Inc. announced that they will report Q4, 2020 results at 4:30 PM, US Eastern Standard Time on Mar 23, 2021
お知らせ • Feb 26Marrone Bio Innovations, Inc., Annual General Meeting, May 26, 2021Marrone Bio Innovations, Inc., Annual General Meeting, May 26, 2021.
Executive Departure • Feb 24President & CFO James Boyd has left the companyOn the 18th of February, James Boyd's tenure as President & CFO ended after 3.5 years in the role. As of December 2020, James personally held 109.29k shares (€108k worth at the time). A total of 2 executives have left over the last 12 months.
Executive Departure • Feb 19President & CFO James Boyd has left the companyOn the 18th of February, James Boyd's tenure as President & CFO ended after 3.5 years in the role. As of December 2020, James personally held 109.29k shares (€108k worth at the time). A total of 2 executives have left over the last 12 months.
お知らせ • Feb 04Marrone Bio Innovations, Inc. Announces Executive ChangesMarrone Bio Innovations, Inc. announced that Kevin Hammill will take on a new role as Chief Manufacturing and Supply Chain Officer. Kevin was critical in revamping and growing the commercial organization in short order, and his leadership as Chief Commercial Officer has played a major role in their success. Matti Tiainen is being promoted to Senior Vice President of International Sales, with responsibilities for their commercial activities in EMEA/CIS, South America and Asia Pacific. Tim Knight will be sharing commercial responsibilities with Matti as Senior Director of Sales, North and Central America. While relatively new to Marrone Bio, Tim has more than 30 years of experience in agriculture with excellent skills in sales, marketing, product development and channel management.
Is New 90 Day High Low • Jan 30New 90-day high: €1.34The company is up 44% from its price of €0.93 on 30 October 2020. The German market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 28% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.60 per share.
お知らせ • Jan 29Marrone Bio Innovations, Inc. Announces Management ChangesMarrone Bio Innovations, Inc. announced that Suping (Sue) Cheung has been appointed Chief Financial Officer, effective Feb. 18, 2021. She succeeds James Boyd, who previously announced his intention to retire. Cheung, a certified public accountant, brings to Marrone Bio 28 years of experience in international strategic and financial operations, including financial reporting, forecasting and budgeting; mergers and acquisitions; equity and debt financing; internal controls; and investor relations. Most recently, she was the chief financial officer for QuickLogic Corporation (NASDAQ: QUIK) for five years, and corporate controller in the eight years before that promotion. Prior to QuickLogic, she has held senior roles at both publicly traded and privately held companies in accounting, finance and operational management, and began her career as an auditor and tax consultant at PricewaterhouseCoopers (PwC).
お知らせ • Jan 15Marrone Bio Innovations Recently Receives Approval for Grandevo WDG Bioinsecticide for Use in New Zealand and ChileMarrone Bio Innovations, Inc. announced that it recently received approval for Grandevo WDG Bioinsecticide for use in New Zealand and Chile. Grandevo WDG and Grandevo CG have also been approved for use on hemp by the U.S. Environmental Protection Agency (EPA). In New Zealand, Grandevo WDG will be sold by Nufarm as BioGro® and is approved for controlling mealybug on New Zealand’s famous wine grape crop. BioGro is registered and approved by Sustainable Winegrowing NZ™ (SWNZ), a sustainability program for growing wine grapes, and is allowed for use on both organic and conventional grape-growing systems from pre-flowering to bunch closure. Additional crops and pests are expected for approval in the coming year. Grandevo WDG was approved for use in blueberries, grapes, stone fruit, tomatoes, avocados, and onions by the Ministry of Agriculture in Chile (Servicio Agricola y Ganadero - SAG) in November 2020 and is distributed by Anasac, a leading Chilean agriculture inputs provider. Grandevo WDG was among one of the first products of its kind to be approved under SAG’s new regulatory guidance (No. 9074/2018) for biological pesticides, as published in December 2018. Chile is a major exporter of fresh blueberries and grapes and accounts for 60% of all fruit exports within South America. In the U.S., Grandevo WDG and Grandevo CG were recently approved by the EPA for use on hemp, a high-value crop that has seen rapid growth since its authorization for cultivation in the 2014 U.S. Farm Bill. The approval of the bioinsecticide will provide growers with some much-needed help in the management of problematic pests such as thrips and mites and comes at a time when, due to the highly regulated environment of hemp growing and processing, limited crop protection products have been available. Growers are encouraged to check with their state pesticide regulatory agency or MBI for registration status and can expect state approval in time for the planting of the 2021 hemp crop.
Is New 90 Day High Low • Jan 14New 90-day high: €1.12The company is up 16% from its price of €0.96 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.74 per share.
Analyst Estimate Surprise Post Earnings • Nov 11Revenue misses expectationsRevenue missed analyst estimates by 15%. Over the next year, revenue is forecast to grow 47%, compared to a 3.1% growth forecast for the Chemicals industry in Germany.
Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.04 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$8.83m (up 27% from 3Q 2019). Net loss: US$6.06m (loss narrowed 63% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 03Marrone Bio Innovations, Inc. Announces Appointment of Lara L. Lee as Class III DirectorMarrone Bio Innovations, Inc. announced that on November 2, 2020, following 2020 Annual Meeting, Board of Directors approved an increase in the size of the Board to eight people, with the one additional vacancy on the Board being in Class III, effective immediately. The Board appointed Lara L. Lee to fill the vacancy as a Class III director of the Company, with Ms. Lee's term to expire as of 2022 Annual Meeting of Stockholders. Ms. Lee will serve on the Audit Committee and Compensation Committee of the Board. Most recently, since 2018, Ms. Lee has served as the Chief Executive Officer of Creative Renewal. Ms. Lee currently serves on the boards of Organically Grown Company and The Sill.
お知らせ • Oct 28Marrone Bio Innovations, Inc. to Report Q3, 2020 Results on Nov 09, 2020Marrone Bio Innovations, Inc. announced that they will report Q3, 2020 results on Nov 09, 2020
Is New 90 Day High Low • Oct 14New 90-day low: €0.91The company is down 7.0% from its price of €0.97 on 16 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €5.94 per share.
お知らせ • Sep 23+ 1 more updateJames Boyd to Retire as President of Marrone Bio Innovations, IncMarrone Bio Innovations, Inc. announced that company President James Boyd will retire from his positions. A national search process for the new Chief Financial Officer is underway, and Mr. Boyd will continue as President during the search process.
お知らせ • Jul 25Marrone Bio Innovations, Inc. to Report Q2, 2020 Results on Aug 10, 2020Marrone Bio Innovations, Inc. announced that they will report Q2, 2020 results at 4:30 PM, US Eastern Standard Time on Aug 10, 2020
お知らせ • Jul 07Marrone Bio Innovations, Inc. Appoints Kevin Helash as New Chief Executive OfficerMarrone Bio Innovations, Inc. announced the appointment of Kevin Helash as its new chief executive officer. Helash will join the company as early as August 1, 2020. His effective date is pending receipt of permanent residency status or the applicable visa, both of which are in process. A 28-plus-year agricultural industry veteran, Helash comes to Marrone Bio from Agrinos AS. Prior to joining Agrinos, Helash was a vice president and corporate officer with Agrium (now Nutrien Ltd.). Helash replaces Pamela Marrone, founder of Marrone Bio, who announced her intention to retire as CEO in December 2019. Marrone will remain with Marrone Bio as CEO until Helash’s first day of employment and thereafter will continue to serve as a non-employee director of the company.
